Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Marta, Olesnyckyj"'
Autor:
Jean-Luc Harousseau, Meletios A. Dimopoulos, Michael Wang, Alessandro Corso, Christine Chen, Michel Attal, Andrew Spencer, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, Donna M. Weber
Publikováno v:
Haematologica, Vol 95, Iss 10 (2010)
Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the out
Externí odkaz:
https://doaj.org/article/ebc7dccaccd24460a4e984685c397be8
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide
Autor:
Rami S. Komrokji, Rachid Baz, William S. Dalton, Robert Knight, Shalaka S. Hampras, Ji-Hyun Lee, Melissa Alsina, Laurie Kenvin, Taiga Nishihori, Daniel M. Sullivan, Qiang Xu, Marta Olesnyckyj, Dana E. Rollison, William J. Fulp, Kate Fisher, Kenneth H. Shain
Publikováno v:
Leuk Lymphoma
Risk of subsequent primary malignancies (SPMs) associated with lenalidomide therapy in multiple myeloma (MM) patients, outside the context of melphalan-based therapy is not established. We assessed the risk of SPMs in lenalidomide treated MM patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8af84cf6bf133111f38cd793acec245
https://pubmed.ncbi.nlm.nih.gov/27424609
https://pubmed.ncbi.nlm.nih.gov/27424609
Autor:
Zhinuan Yu, Carlos M. de Castro, Meletios A. Dimopoulos, Donna E. Reece, Edward A. Stadtmauer, Zvenyslava Masliak, Marta Olesnyckyj, Jeffrey A. Zonder, Hartmut Goldschmidt, Adrian Alegre, Donna M. Weber
Publikováno v:
Cancer
BACKGROUND: In patients with multiple myeloma, renal impairment (RI) at the time of diagnosis is associated with poor survival. To the authors' knowledge, the current retrospective analysis presented is the first to assess the impact of various degre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0216a1ae6c701f8417697323ba861df4
https://doi.org/10.1002/cncr.25139
https://doi.org/10.1002/cncr.25139
Autor:
Joan Bladé, Wiesław Wiktor Jędrzejczak, Zhinuan Yu, Mohamad A. Hussein, Jerome B. Zeldis, S. Vincent Rajkumar, Lela M. Lucy, Marta Olesnyckyj, Laura Rosiñol, John G. Catalano, Rob Knight
Publikováno v:
Journal of Clinical Oncology. 26:2171-2177
Purpose The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown. The goal of this study was to compare thalidomide plus dexamethasone versus placebo plus dexamethasone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e07e096872264ca4be03e3667d2a4f
https://doi.org/10.1200/jco.2007.14.1853
https://doi.org/10.1200/jco.2007.14.1853
Autor:
Donna M. Weber, David S. Siegel, Marta Olesnyckyj, Jean Luc Harousseau, Jesús F. San-Miguel, Edward A. Stadtmauer, Marie Laure Casadebaig Bravo, Jerome B. Zeldis, Robert Knight, Meletios A. Dimopoulos, S. Vincent Rajkumar
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: In two randomized phase III trials (MM-009 and MM-010), lenalidomide plus dexamethasone significantly prolonged time to progression and overall survival (OS) in patients with relapsed/refractory multiple myeloma compared with dexamethas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b00a448f18d97f2cdf724790124321e1
https://pubmed.ncbi.nlm.nih.gov/21273172
https://pubmed.ncbi.nlm.nih.gov/21273172
Autor:
Michael Wang, Alessandro Corso, Jerome B. Zeldis, Donna M. Weber, Jean Luc Harousseau, Andrew Spencer, Marta Olesnyckyj, Meletios A. Dimopoulos, Zhinuan Yu, Michel Attal, Christine Chen, Robert Knight
Background This retrospective pooled analysis of two phase III trials (MM-009/MM-010) compared clinical outcomes of patients who achieved a complete response or very good partial response to treatment with lenalidomide plus dexamethasone with the out
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc726feaff7a9bbfbd3ce21efb85e738
https://europepmc.org/articles/PMC2948100/
https://europepmc.org/articles/PMC2948100/
Autor:
Robert Vescio, David Irwin, Stephanie F. Williams, Marta Olesnyckyj, Paul G. Richardson, Mohamad A. Hussein, William I. Bensinger, Seema Singhal, James R. Berenson, Jerome B. Zeldis, Zhinuan Yu, Robert Knight, Sundar Jagannath, Laurie Kenvin, Ashraf Badros, Kenneth C. Anderson
Publikováno v:
Blood. 114(4)
Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting. We evaluated the efficacy and safety of lenalidomide monotherapy in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18c40a43baad865a95ec27d60d26b94a
https://pubmed.ncbi.nlm.nih.gov/19471019
https://pubmed.ncbi.nlm.nih.gov/19471019
Autor:
Jerome B. Zeldis, Michel Attal, Christine Chen, Robert Knight, Zhinuan Yu, Michael Wang, Andrew Spencer, M. Teresa Cibeira, Marta Olesnyckyj, S. Vincent Rajkumar, Donna M. Weber, Meletios A. Dimopoulos
Publikováno v:
Blood. 112(12)
This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide. Of 704 patients, 39% were thalidomide exposed. Thalidomide-exposed patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b870a32b60edd46ab0ebf5733b7c32
https://pubmed.ncbi.nlm.nih.gov/19390545
https://pubmed.ncbi.nlm.nih.gov/19390545
Autor:
Andrew Belch, Sagar Lonial, Christine Chen, Jerome B. Zeldis, Michael Wang, Ivan Borrello, Zhinuan Yu, Ruben Niesvizky, Donna M. Weber, David S. Siegel, Marta Olesnyckyj, Robert Knight, Asher A. Chanan-Khan, John Patin, Edward A. Stadtmauer, S. Vincent Rajkumar
Publikováno v:
The New England journal of medicine. 357(21)
Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma.Patients in the United States and Canada who had received at least one pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78c4dbb9deab55c1a71f924ddfe99df
https://pubmed.ncbi.nlm.nih.gov/18477992
https://pubmed.ncbi.nlm.nih.gov/18477992
Autor:
Meletios, Dimopoulos, Andrew, Spencer, Michael, Attal, Miles Prince, H., Jean Luc Harousseau, Anna, Dmoszynska, San Miguel, J., Andrzej, Hellmann, Thierry, Facon, Foa, Roberto, Alessandro, Corso, Zvenyslava, Masliak, Marta, Olesnyckyj, Zhinuan, Yu, John, Patin, Zeldis, Jerome B., Knight, Robert D., Multiple Myeloma Study Investigators
Lenalidomide is a structural analogue of thalidomide with similar but more potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of lenalidomide plus dexamethasone in the treatment of relapsed or refractory multip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36610e232f502a0cc6d7943565788fdd
http://hdl.handle.net/11573/35194
http://hdl.handle.net/11573/35194